The FDA has approved pirtobrutinib (Jaypirca) as a first-line treatment for chronic lymphocytic leukemia and small lymphocytic lymphoma — the most common forms of adult leukemia — in patients without a 17p deletion. This non-covalent BTK inhibitor works differently from older targeted therapies, potentially overcoming drug resistance. In the BRUIN-CLL-313 trial, pirtobrutinib reduced the risk of disease progression or death by 80% compared to standard chemoimmunotherapy. The overall response rate was 94% versus 81% for the chemotherapy combination. Since many CLL patients today receive only one or two lines of therapy — partly due to age and other health conditions — the choice of initial treatment is especially critical. This approval expands pirtobrutinib's role from a later-line option to a frontline standard of care.
